

Dr. med. Eva Ebnöther

Nicht-kleinzelliges Lungenkarzinom – aktuelle Tendenzen der Therapie

Bibliografie

- ¹ Westeel V, et al.: Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC). *Ann Oncol* 2017; 28(suppl 5): Abs 12730, ESMO 2017.
- ² Curioni-Fontecedro A, et al.: Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK. *Ann Oncol* 2017; 28(suppl 5): Abs 1287PD, ESMO 2017.
- ³ Antonia S, et al.: Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med* 2017; 377; 1919–1929.
- ⁴ Ramalingam S, et al.: Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. *Ann Oncol* 2017; 28(suppl 5): Abs LBA2_PR, ESMO 2017.
- ⁵ Novello S, et al.: Primary results form the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ NSCLC. *Ann Oncol* 2017; 28(suppl 5): Abs 12990_PR, ESMO 2017.
- ⁶ Peters S, et al.: Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2017 Aug 31; 377(9): 829–838.